|Bid||77.00 x 800|
|Ask||77.00 x 1300|
|Day's Range||76.95 - 77.76|
|52 Week Range||64.27 - 89.54|
|PE Ratio (TTM)||29.31|
|Earnings Date||Jul 25, 2018|
|Forward Dividend & Yield||2.28 (3.03%)|
|1y Target Est||86.00|
Who has the most productive workforce in the Bay Area, and how much does each employee rake in per year, on average?
The next big market for biopharma could be nonalcoholic steatohepatitis, so upcoming data from these companies could be market-moving.
Gilead Sciences, Inc. (GILD) announced today that its second quarter 2018 financial results will be released on Wednesday, July 25, after the market closes. At 5:00 p.m. Eastern Time, Gilead’s management will host a conference call to discuss the company’s financial results for the second quarter 2018 and provide a general business update. Alternatively, please call 1-877-359-9508 (U.S.) or 1-224-357-2393 (international) and dial the conference ID 8988927 to access the call.
Gilead Sciences Inc. ( GILD) stock may be finally starting to show a revival after three years of sharp declines, dragging the stock down by over 30%. Options traders are betting the rally in Gilead will continue as well, and they see the stock rising to about $82 by the middle of August. The longer-term outlook for Gilead still proves to be questionable with the company still facing declining revenues as it rebuilds its drug pipeline.
Celgene Corporation (NASDAQ:CELG) stock looks attractive here, for a number of reasons. Celgene stock has sold off, losing about 43% of its value. Celgene touched a four-year low in May before a recent rebound. The decline leaves Celgene looking awfully cheap, at a little over 8.3x 2019 consensus EPS estimates.
Biotech is a notoriously risky business. Many biotechnology products do not produce the desired results consistently, while others fail to gain acceptance in the marketplace. Of course, when a biotech product succeeds, investors can make a lot of money.
The following four stocks are currently in the midst of uptrends according to VantagePoint, an AI charting platform that uses intermarket analysis and artificial intelligence to predict future price action 1-3 days in advance. The blue line is a predicted moving average that forecasts a stock's moving average two days out. Ford Motor Company (NYSE: F) was on a clear downtrend starting on June 13, but that looks to have ended for now as the stock has bounced off the $11 level.
To receive further updates on this Gilead Sciences (NASDAQ:GILD) trade, sign up for a risk-free trial of Maximum Options today. XLF bounced briefly earlier this week, but it remains below all of its major moving averages.
Kite, a Gilead Company (GILD), announced today that Michael Amoroso will join the company as Senior Vice President and Head of Worldwide Commercial, Cell Therapy. In this position, Mr. Amoroso will have responsibility for Kite’s commercial organization including sales, marketing, market access, and healthcare provider and patient services.
The large-cap biotech stocks have been left in the dust this year with the iShares Nasdaq Biotechnology ETF ( IBB) rising by only 8.7%. This, by most standards, is a healthy gain compared to the S&P 500 rise of only 3%. Signs are emerging that the larger-cap biotechs are poised to break out in the near term, and that could send stocks like Celgene Corp. ( CELG), Gilead Sciences, Inc. ( GILD), Amgen Inc. ( AMGN) and Alexion Pharmaceuticals, Inc. ( ALXN) much higher.
Several major biotech stocks rallied on Friday after Biogen (BIIB) reported positive results from a Phase 2 study of its Ban2401 therapy, which seeks to reduce toxic amyloid proteins associated with cognitive decline and Alzheimer's disease.
In the search for investments with long-term growth potential, an increasing number of funds, and fund managers, are focusing on companies that score high on so-called Environmental, Social and Governance (ESG) criteria.
The NASDAQ Biotechnology Index rose about 3% in midday trading Friday to 3,636.45, the highest level since February. underperforming the overall NASDAQ Index in the past year, investors might be recognizing the hidden value of the firms' drug research and development, says Steve Chesney, an analyst for Atlantic Equities in London who covers large cap biotech firms worth more than $60 billion. Celgene, a biotechnology company which develops anti-inflammatory drugs for cancer and other diseases rose around 2% to $82.09 in early afternoon trading.
The daily chart looks like it could use more development but the weekly bar chart shows us a strong bottom formation. In the daily bar chart of GILD, below, you can see a wide swinging market. Now you have to really look at the daily On-Balance-Volume (OBV) line.
NEW YORK, NY / ACCESSWIRE / July 6, 2018 / U.S. markets rose Thursday on the strength of the technology sector, yet investors appear to be apprehensive as the U.S. prepare to place tariffs on Chinese goods. ...
Key headlines in the biotech sector last week include Gilead getting positive CHMP opinion, Keryx plunging on merger news while Celgene and Amgen came out with pipeline updates.
Yahoo Finance’s Seana Smith and Jared Blikre with up-to-the-minute market analysis and the biggest headlines in midday trading Tuesday.